Works matching IS 17562856 AND DT 2010 AND VI 3 AND IP 1

Results: 6
    1

    A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS).

    Published in:
    Therapeutic Advances in Neurological Disorders, 2010, v. 3, n. 1, p. 3, doi. 10.1177/1756285609355851
    By:
    • Remington, Gina M.;
    • Treadaway, Katherine;
    • Frohman, Teresa;
    • Salter, Amber;
    • Stüve, Olaf;
    • Racke, Michael K.;
    • Hawker, Kathleen;
    • Agosta, Federica;
    • Sormani, Maria Pia;
    • Filippi, Massimo;
    • Frohman, Elliot M.
    Publication type:
    Article
    2

    A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

    Published in:
    Therapeutic Advances in Neurological Disorders, 2010, v. 3, n. 1, p. 15, doi. 10.1177/1756285609353354
    By:
    • Frohman, Elliot M.;
    • Cutter, Gary;
    • Remington, Gina;
    • Gao, Hongjiang;
    • Rossman, Howard;
    • Weinstock-Guttman, Bianca;
    • Durfee, Jacqueline E.;
    • Conger, Amy;
    • Carl, Ellen;
    • Treadaway, Katherine;
    • Lindzen, Eric;
    • Salter, Amber;
    • Frohman, Teresa C.;
    • Shah, Anjali;
    • Bates, Angela;
    • Cox, Jennifer L.;
    • Dwyer, Michael G.;
    • Stuve, Olaf;
    • Greenberg, Benjamin M.;
    • Racke, Michael K.
    Publication type:
    Article
    3
    4
    5
    6